243 related articles for article (PubMed ID: 23018281)
1. A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.
Lee SJ; Lee JH; Jung SW; Koo BH; Choi TY; Lee KH
Clin Drug Investig; 2012 Nov; 32(11):735-45. PubMed ID: 23018281
[TBL] [Abstract][Full Text] [Related]
2. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
Chabannes JP; Pelissolo A; Farah S; Gerard D
Encephale; 1998; 24(4):386-92. PubMed ID: 9809244
[TBL] [Abstract][Full Text] [Related]
4. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.
Freeman HL
Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S11-7. PubMed ID: 9218163
[TBL] [Abstract][Full Text] [Related]
5. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group.
Puech A; Fleurot O; Rein W
Acta Psychiatr Scand; 1998 Jul; 98(1):65-72. PubMed ID: 9696517
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness and tolerability of amisulpride in patients with schizophrenia: results of a 6-month open study].
Rzewuska M; Kuczyński W; Luks M
Psychiatr Pol; 2004; 38(3):453-68. PubMed ID: 15199655
[TBL] [Abstract][Full Text] [Related]
7. Clinical update on amisulpride in deficit schizophrenia.
Rein W; Turjanski S
Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S19-27. PubMed ID: 9218164
[TBL] [Abstract][Full Text] [Related]
8. Practical issues with amisulpride in the management of patients with schizophrenia.
Pani L; Villagrán JM; Kontaxakis VP; Alptekin K
Clin Drug Investig; 2008; 28(8):465-77. PubMed ID: 18598092
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients.
Riedel M; Eich FX; Möller HJ
Eur Psychiatry; 2009 Apr; 24(3):149-53. PubMed ID: 19070995
[TBL] [Abstract][Full Text] [Related]
10. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.
Bhowmick S; Hazra A; Ghosh M
Aust N Z J Psychiatry; 2010 Mar; 44(3):237-42. PubMed ID: 20050717
[TBL] [Abstract][Full Text] [Related]
11. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.
Müller MJ; Wetzel H; Eich FX; Rein W; Puech A; Benkert O;
J Clin Psychopharmacol; 2002 Dec; 22(6):554-60. PubMed ID: 12454554
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature].
Pélissolo A; Krebs MO; Olié JP
Encephale; 1996; 22(3):215-9. PubMed ID: 8767050
[TBL] [Abstract][Full Text] [Related]
13. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.
Hwang TJ; Lee SM; Sun HJ; Lin HN; Tsai SJ; Lee YC; Chen YS
J Formos Med Assoc; 2003 Jan; 102(1):30-6. PubMed ID: 12684609
[TBL] [Abstract][Full Text] [Related]
14. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study.
Genç Y; Taner E; Candansayar S
Adv Ther; 2007; 24(1):1-13. PubMed ID: 17526456
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
[TBL] [Abstract][Full Text] [Related]
16. The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.
Herrera-Estrella M; Apiquian R; Fresan A; Sanchez-Torres I
BMC Psychiatry; 2005 May; 5():22. PubMed ID: 15869707
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.
Colonna L; Saleem P; Dondey-Nouvel L; Rein W
Int Clin Psychopharmacol; 2000 Jan; 15(1):13-22. PubMed ID: 10836281
[TBL] [Abstract][Full Text] [Related]
18. Treatment of negative symptoms in schizophrenia with amisulpride.
Boyer P; Lecrubier Y; Puech AJ; Dewailly J; Aubin F
Br J Psychiatry; 1995 Jan; 166(1):68-72. PubMed ID: 7894879
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
Lin CH; Wang FC; Lin SC; Huang YH; Chen CC; Lane HY
Int Clin Psychopharmacol; 2013 Sep; 28(5):267-74. PubMed ID: 23778382
[TBL] [Abstract][Full Text] [Related]
20. The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study.
Ahn YM; Lee KY; Kim CE; Kang DY; Seok JH; Shin YM; Chung IW; Jun TY; Chang JS; Kim YS
Hum Psychopharmacol; 2011 Dec; 26(8):568-77. PubMed ID: 22139601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
